CLLS — Cellectis SA Income Statement
0.000.00%
Last trade - 00:00
- $146.43m
- -$21.31m
- $9.19m
- 25
- 48
- 40
- 32
2019 December 31st | R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 23 | 59.6 | 38.6 | 25.7 | 9.19 |
Cost of Revenue | |||||
Gross Profit | -37.7 | 13.5 | -27.5 | -18.7 | -30.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 147 | 102 | 142 | 115 | 106 |
Operating Profit | -124 | -42.3 | -103 | -89.7 | -97.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -115 | -53.6 | -96.8 | -98.6 | -116 |
Provision for Income Taxes | |||||
Net Income After Taxes | -115 | -53.6 | -96.8 | -98.7 | -117 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -102 | -81.1 | -114 | -106 | -101 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -102 | -81.1 | -114 | -106 | -101 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.41 | -0.875 | -1.92 | -1.99 | -1.92 |
Dividends per Share |